Gallium (68Ga) edetate ([68Ga]Ga-EDTA)

Gallium-68 edetate ([68Ga]Ga-EDTA) is a radiopharmaceutical coordination complex consisting of the positron-emitting radioisotope Gallium-68 and the hexadentate chelating agent ethylenediaminetetraacetic acid (EDTA) (PubChem CID 15559458). It is primarily utilized as a diagnostic tracer in Positron Emission Tomography (PET) imaging to evaluate physiological functions rather than binding to specific biological receptors. Historically, it has served as a reference standard for measuring the glomerular filtration rate (GFR) due to its stable renal clearance characteristics (Journal of Nuclear Medicine, 1970). Additionally, it is used to detect disruptions in the blood-brain barrier (BBB) associated with primary or metastatic brain tumors, as the complex only enters the brain parenchyma when the barrier is compromised (PubMed PMID: 4696767). Unlike targeted radiopharmaceuticals that interact with specific proteins like PSMA or somatostatin receptors, Ga-68 EDTA acts as a marker of fluid-phase transport and vascular permeability. It is cleared rapidly by the kidneys and exhibits minimal protein binding in the blood. While its use in neuroimaging has largely been superseded by MRI and other PET tracers, it remains a valuable tool for functional nephrology studies. It is not considered a therapeutic target but rather a diagnostic agent for physiological monitoring.

Other names

68Ga-EDTAGallium-68 ethylenediaminetetraacetateGallium-68 edetic acid complexGallium-68 EDTA

Gallium-68 edetate functions as a passive diagnostic tracer. In renal applications, the complex is cleared from the plasma exclusively through glomerular filtration without significant tubular secretion or reabsorption, allowing for the precise measurement of the glomerular filtration rate (GFR) (Journal of Nuclear Medicine, 1970, 11(6):324). In neurology, the hydrophilic nature of the complex prevents it from crossing an intact blood-brain barrier (BBB); therefore, its accumulation in brain tissue serves as a marker for BBB disruption, which is characteristic of certain tumors and inflammatory processes (PubMed PMID: 4696767).